Rhythm Pharmaceuticals Inc (RYTM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $98.58 (-0.44%), Market cap $6.12B, 52-week low–high $59.18 ~ $117.62.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency
Financial statements, price targets, institutional (13F) holdings and related news for Rhythm Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Rhythm Pharmaceuticals Inc trades at $98.58 (-0.44%). Real-time quotes and charts are available on BlackAll Trade.
Rhythm Pharmaceuticals Inc has a market cap of about $6.12B.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate i